Agennix to boost talactoferrin programme
This article was originally published in Scrip
Executive Summary
As Agennix published Phase II results for its recombinant human lactoferrin product, talactoferrin, in non-small cell lung cancer (NSCLC), the company said it was looking to recruit additional experts in much the same way it brought in Dr Steven Simonson from AstraZeneca last month, to boost internal knowledge on sepsis – the other investigational indication for the drug.